Loading…
Loading…
WALLACE, ID / ACCESS Newswire / August 18, 2026 / Magellan Copper & Gold Corp. (OTCID:MAGE) ("Magellan" or the "Company") is pleased to announce that the company's wholly owned subsidiary Magellan Energy Corp. has entered a Letter of Intent to acquire Ramm Power Group. Upon closing of the acquisition, the combined companies will be pursuing brownfield development opportunities in the energy production and storage markets.
WALLACE, ID / ACCESS Newswire / August 13, 2026 / Magellan Copper & Gold Corporation (OTCID:MAGE) ("Magellan" or the "Company"), is pleased to announce that the company has formed a new wholly owned subsidiary, Magellan Energy Corp. The company will pursue opportunities in the energy production and storage markets with an emphasis on brownfield development of efficient energy solutions. Amid an ever-increasing emphasis on data centers to power the new Artificial Intelligence (AI) revolution, the country is seeing huge demand for energy but is stymied in finding faster and more efficient ways to satisfy the increase in demand.
Planned acquisition gives Magellan the ability to produce gold in 2026, and take advantage of the rapid rise in metal prices which could add significant value to shareholders. WALLACE, ID / ACCESS Newswire / January 30, 2026 / Magellan Coper and Gold Corp. (OTCID:MAGE) ("Magellan" or the "Company"), is pleased to announce that the Company has entered into a letter of intent to acquire the Ophir Creek Placer Gold Mine from Village Gold, Inc. The project is located near Ophir, Alaska.
WALLACE, ID / ACCESS Newswire / February 26, 2025 / Magellan Copper and Gold Corp. (OTC PINK:MAGE) ("Magellan" or the "Company"), is pleased to announce that the company has entered into an agreement with Gold Express Mines for a joint venture participatory agreement on the historic Atlantic Cable Gold Mine (the "Cable Mine") located about midway between Anaconda, Montana and Philipsburg, Montana. The Cable Mine is widely considered one of Montana's top tier bonanza-grade gold producers and is known for its museum quality specimen gold.
WALLACE, ID / ACCESSWIRE / January 16, 2024 / Magellan Gold Corporation (OTC PINK:MAGE) ("Magellan" or the "Company"), is pleased to announce that the company has entered into an agreement with Gold Express Mines, Inc. for the purchase of three copper-focused properties, two of which are in Idaho, and one in Arizona. The Copper Cliff Property, in Adams County, Idaho, is located about nine miles north of the town of Cuprum, Idaho.
WALLACE, ID / ACCESSWIRE / January 8, 2024 / Magellan Gold Corporation (OTC PINK:MAGE) ("Magellan" or the "Company"), is pleased to announce that the Company has entered into a certain agreements with AJB Capital Investments LLC ("ABJ") and Gold Express Mines, Inc. ("GEM") pursuant to which AJB assigned to GEM all of ABJ's right, title, obligation, liability and interest in that certain Promissory Note, dated February 2021 (the "Promissory Note"), issued by the Company to AJB. The aggregate principal amount of the Promissory Note outstanding is $100,000.
SAN FRANCISCO--(BUSINESS WIRE)--Today, Humble Games, the publishing team of the beloved Humble Bundle brand, debuted the Humble Games Showcase to a public audience, sharing insight into their slate for 2023 and beyond. During the showcase, the team doubled down on the company’s dedication to high-quality indie games that deliver approachable yet deeply original experiences for players worldwide. Fans from around the world were treated to the reveals of six new titles, led by Wizard of Legend 2 from Dead Mage, which is now a Humble Games owned IP, and Lost Skies from Bossa Studios, one of the biggest and most ambitious indie titles from the publisher to date. In addition to this the team revealed new game updates from previously announced titles and a surprise game launch. "We're incredibly excited for players to get their hands on our newly announced lineup as we continue to focus on supporting our development partners to bring their creative visions to life—and help them make their games the best they can be,” said Mark Nash, Humble’s Vice President of Global Publishing. "2022 was another very successful year for us, adding several more critically acclaimed and award-winning titles like SIGNALIS, Ghost Song and Prodeus to our growing portfolio. Our future lineup is proof of our continued investment in supporting our development partners to push the boundaries with their games.” Expanding their publishing efforts, Humble Games revealed Wizard of Legend 2, the follow-up to one of its most popular games to date, and announced that it will be the second wholly owned franchise for the company following last year’s announcement of Monaco II. Continuing the excitement, Humble Games also revealed the co-op open world survival adventure Lost Skies with an exclusive early look at the game presented by the groundbreaking team at Bossa Studios. In addition, Humble Games revealed several more new games, including Breeze in the Clouds, a 2D hand-drawn side-scrolling action game focused on environmentalism—and the second Humble-published game to come from Humble’s Black Game Developer Fund—#BLUD, a delightfully zany dungeon crawler; Bō: Path of the Teal Lotus, a hand-drawn 2D action platformer based in a world of Japanese folklore; and Cataclismo, a fortress-building real-time strategy game set in a dark medieval fantasy realm. Updates for the highly anticipated Stray Gods: The Roleplaying Musical were also announced along with a surprise launch of the first-person metroidvania Supraland: Six Inches Under on PlayStation, Xbox and Game Pass. The event also included an update on Humble’s charitable giving from VP of Social Impact Kamini Tiwari. In 2022, Humble raised a company record $33 million for people and causes in need, benefiting more than ten thousand charities. These efforts included Humble’s Stand with Ukraine all-for-charity bundle, which raised more than $20 million and just won a prestigious Gold Halo Award from Engage for Good. In addition, Humble Games revealed that Protodroid DeLTA, which launches May 25, 2023, will have a Day One DLC Armor Pack, with 100% of proceeds being donated to the Girls Make Games Scholarship Fund. More details about Humble’s charitable giving can be found in the recently released 2022 Social Impact Report here. Information on all the games highlighted during the Humble Game Showcase can be found below: Lost Skies Humble Games and Bossa Games unveiled their upcoming game Lost Skies. Lost Skies is a cooperative survival adventure for 1–6 players set among the clouds, in a vast sky of floating islands. Find and craft ancient technology, build your own skyship, brave ferocious storms, and battle giant threats that await beyond the horizon. Check out the Lost Skies Official Animated Reveal Trailer here. Downloadable assets can be found here. The developer interview can be found on YouTube here. Humble Games and Bossa Games unveiled their upcoming game Lost Skies. Lost Skies is a cooperative survival adventure for 1–6 players set among the clouds, in a vast sky of floating islands. Find and craft ancient technology, build your own skyship, brave ferocious storms, and battle giant threats that await beyond the horizon. Check out the Lost Skies Official Animated Reveal Trailer here. Downloadable assets can be found here. The developer interview can be found on YouTube here. Check out the Lost Skies Official Animated Reveal Trailer here. Downloadable assets can be found here. The developer interview can be found on YouTube here. Wizard of Legend 2 Humble Games announced their second owned title, Wizard of Legend 2, which is being developed by Dead Mage with guidance from original developer Contingent 99. Wizard of Legend 2 is an action-packed follow-up to the acclaimed dungeon-delving original. The game will feature vibrant new 3D visuals and fast-paced 4-player online co-op. Wield familiar and new Arcana, experiment with devious new spell combinations, and return again and again (and again) to master ever-changing rogue-lite challenges of the Chalice of Immortality. Check out the Wizard of Legend 2 Official Announcement Trailer here. Downloadable assets can be found here. Humble Games announced their second owned title, Wizard of Legend 2, which is being developed by Dead Mage with guidance from original developer Contingent 99. Wizard of Legend 2 is an action-packed follow-up to the acclaimed dungeon-delving original. The game will feature vibrant new 3D visuals and fast-paced 4-player online co-op. Wield familiar and new Arcana, experiment with devious new spell combinations, and return again and again (and again) to master ever-changing rogue-lite challenges of the Chalice of Immortality. Check out the Wizard of Legend 2 Official Announcement Trailer here. Downloadable assets can be found here. Check out the Wizard of Legend 2 Official Announcement Trailer here. Downloadable assets can be found here. #BLUD (PC, 2024) Humble Games shared a new publishing partnership with animation studio and developer Exit 73 on their debut game, #BLUD. #BLUD is a delightfully zany dungeon crawler that blends the line between video game and cartoon. Take on the role of plucky teen Becky Brewster as you balance school, friends, field hockey and fiend-slaying in this creative take on the traditional action RPG. Unique, high-quality 2D animation filled with personality and humor brings the world and characters of #BLUD to life in this one-of-a-kind animated adventure. Check out the #Blud Official Announcement Trailer here. Downloadable assets can be found here. Humble Games shared a new publishing partnership with animation studio and developer Exit 73 on their debut game, #BLUD. #BLUD is a delightfully zany dungeon crawler that blends the line between video game and cartoon. Take on the role of plucky teen Becky Brewster as you balance school, friends, field hockey and fiend-slaying in this creative take on the traditional action RPG. Unique, high-quality 2D animation filled with personality and humor brings the world and characters of #BLUD to life in this one-of-a-kind animated adventure. Check out the #Blud Official Announcement Trailer here. Downloadable assets can be found here. Check out the #Blud Official Announcement Trailer here. Downloadable assets can be found here. Bō: Path of the Teal Lotus (PC, 2024) Humble Games and Squid Shock Studios revealed that Humble would be publishing the developer’s first-ever game, Bō: Path of the Teal Lotus, a hand-drawn 2.5D action platformer based in a world of Japanese folklore. Take on the role of the Celestial Blossom Bō as you master your shapeshifting abilities, brew arcane teas to unlock celestial powers, and explore a mysterious haunted world filled with adorable and otherworldly characters straight from legend and myth. Check out the Bō: Path of the Teal Lotus Official Announcement Trailer here. Downloadable assets can be found here. Humble Games and Squid Shock Studios revealed that Humble would be publishing the developer’s first-ever game, Bō: Path of the Teal Lotus, a hand-drawn 2.5D action platformer based in a world of Japanese folklore. Take on the role of the Celestial Blossom Bō as you master your shapeshifting abilities, brew arcane teas to unlock celestial powers, and explore a mysterious haunted world filled with adorable and otherworldly characters straight from legend and myth. Check out the Bō: Path of the Teal Lotus Official Announcement Trailer here. Downloadable assets can be found here. Check out the Bō: Path of the Teal Lotus Official Announcement Trailer here. Downloadable assets can be found here. Breeze in the Clouds Humble Games and Stormy Nights Interactive announced Humble will be publishing Breeze in the Clouds, with an interview with the developer, SrBilyon Harris, and a new trailer. The game features a corgi named Breeze who gets swept away from his home and from his best friend Diana, and whisked into the weather world of Tropolis. Breeze will need to use his newfound powers to assume an array of weather-based forms, fight the forces of pollution poisoning the world, and become an unstoppable force of nature. Check out the Breeze in the Clouds Official Announcement Trailer here. Downloadable assets can be found here. Humble Games and Stormy Nights Interactive announced Humble will be publishing Breeze in the Clouds, with an interview with the developer, SrBilyon Harris, and a new trailer. The game features a corgi named Breeze who gets swept away from his home and from his best friend Diana, and whisked into the weather world of Tropolis. Breeze will need to use his newfound powers to assume an array of weather-based forms, fight the forces of pollution poisoning the world, and become an unstoppable force of nature. Check out the Breeze in the Clouds Official Announcement Trailer here. Downloadable assets can be found here. Check out the Breeze in the Clouds Official Announcement Trailer here. Downloadable assets can be found here. Cataclismo Humble Games and Digital Sun shared a reveal trailer for Cataclismo, a fortress-building game set in a dark medieval fantasy realm. By the creators of Moonlighter and The Mageseeker, the game sees players leading an expedition beyond the gates of the last city, constructing fortresses and defending against waves of Horrors in a mix of tower defense and real-time strategy, as they reclaim mist-shrouded ruins and rebuild humanity—stone by stone. Check out the Cataclismo Official Announcement Trailer here. Downloadable assets can be found here. Humble Games and Digital Sun shared a reveal trailer for Cataclismo, a fortress-building game set in a dark medieval fantasy realm. By the creators of Moonlighter and The Mageseeker, the game sees players leading an expedition beyond the gates of the last city, constructing fortresses and defending against waves of Horrors in a mix of tower defense and real-time strategy, as they reclaim mist-shrouded ruins and rebuild humanity—stone by stone. Check out the Cataclismo Official Announcement Trailer here. Downloadable assets can be found here. Check out the Cataclismo Official Announcement Trailer here. Downloadable assets can be found here. Stray Gods: The Roleplaying Musical (PC, August 3, 2023) Humble Games and Summerfall Studios shared more insight into Stray Gods: The Roleplaying Musical, which will be launching on August 3, 2023, with a behind-the-scenes look at their recent in-person Myth & Music event at the El Rey Theater. Stray Gods is one part narrative-driven adventure and one part interactive musical, created by former BioWare lead writer David Gaider, scored by award-winning composer Austin Wintory, voice directed by acclaimed actor and director Troy Baker and starring the incredible Laura Bailey along with a full cast of extremely talented voice actors. Check out the Stray Gods: The Roleplaying Musical Official Release Date Trailer here. Downloadable assets can be found here. Humble Games and Summerfall Studios shared more insight into Stray Gods: The Roleplaying Musical, which will be launching on August 3, 2023, with a behind-the-scenes look at their recent in-person Myth & Music event at the El Rey Theater. Stray Gods is one part narrative-driven adventure and one part interactive musical, created by former BioWare lead writer David Gaider, scored by award-winning composer Austin Wintory, voice directed by acclaimed actor and director Troy Baker and starring the incredible Laura Bailey along with a full cast of extremely talented voice actors. Check out the Stray Gods: The Roleplaying Musical Official Release Date Trailer here. Downloadable assets can be found here. Check out the Stray Gods: The Roleplaying Musical Official Release Date Trailer here. Downloadable assets can be found here. Supraland: Six Inches Under (AVAILABLE ON PLAYSTATION, XBOX AND GAME PASS TODAY!) Humble Games and Supra Games UG shared the surprise Playstation, Xbox and Game Pass launch for their beloved first-person-metroidvania, Supraland: Six Inches Under. In Supraland: Six Inches Under, players can unearth what’s beneath the surface in this miniature land of big adventure full of puzzles, exploration, fun secrets to discover and more. Check out the Supraland: Six Inches Under Official Console Launch Trailer here. Downloadable assets can be found here. Humble Games and Supra Games UG shared the surprise Playstation, Xbox and Game Pass launch for their beloved first-person-metroidvania, Supraland: Six Inches Under. In Supraland: Six Inches Under, players can unearth what’s beneath the surface in this miniature land of big adventure full of puzzles, exploration, fun secrets to discover and more. Check out the Supraland: Six Inches Under Official Console Launch Trailer here. Downloadable assets can be found here. Check out the Supraland: Six Inches Under Official Console Launch Trailer here. Downloadable assets can be found here. Fans can relive all of the exciting reveals and announcements of the Humble Games Showcase 2023 on YouTube here. To stay up to date on the latest, follow Humble Games on Twitter, YouTube, Instagram and Facebook. About Humble Games: Best known for critically acclaimed and award-winning hits such as A Hat in Time, Forager, Project Wingman, SIGNALIS, Slay the Spire, Temtem, UNSIGHTED, Unpacking and Wizard of Legend, Humble Games is Humble Bundle’s publishing arm, composed of a passionate and nimble team that works remotely with a collection of talented global development partners. Humble Games was founded on a shared passion to support developers and deliver excellent content and gaming experiences to players around the world, while continuing the Humble mission to be a force for good in the industry. Humble Games is committed to investing in top quality games, comprising both new and existing beloved IPs, all while prioritizing and supporting developer partnerships so that they can focus on bringing their creative visions to life.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company’s platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers. The data were shared in three presentations at this year’s American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Los Angeles, California. “We’re excited to present new data related to our programs in acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors,” said Philip Gregory, D.Phil., chief scientific officer, 2seventy bio. “These presentations provide further evidence of our focus on generating potent and targeted anti-tumor activity while limiting toxicity through innovative approaches to controlling T cell responses. With this approach, we believe we can augment the tremendous potential of cell-based immunotherapy, with the goal of advancing next-generation treatments targeting a broad range of cancer types.” bbT369, a dual-targeted and CBLB gene edited autologous CAR T product for non-Hodgkin lymphoma, showed edit-driven enhanced activity in preclinical in vitro and in vivo models bbT369 is 2seventy’s novel investigational CD79a/CD20 dual-targeting CBLB gene edited CAR T cell therapy for the treatment of patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). This preclinical study evaluated the role of the CBLB edit across multiple aspects of CAR T cell function compared to unedited controls. In the study, in vitro assays were designed to model known challenges to maximal CAR T cell activity within the tumor, such as chronic activation, antigen downregulation, and immunosuppression. The data demonstrated that the CBLB gene edit significantly enhanced the activity of the bbT369 CAR T cells across each of the in vitro model systems tested. bbT369 T cells also drove greater T cell expansion and durable tumor control compared with unedited controls in vivo using a xenograft NSG mouse model. RESET, a novel TCR coupled antigen receptor architecture, showed targeting sensitivity and pharmacologically- controlled anti-tumor activity in models of acute myeloid leukemia For some tumors, available target antigens lack ideal expression, necessitating improvements in targeting sensitivity, potency, control, and/or exhaustion mitigation to achieve robust anti-tumor efficacy. While classical CAR T cells require high levels of target antigen for maximum activity, the endogenous T cell receptor (TCR) is significantly more sensitive to low target antigen abundance. To address this gap, a novel receptor architecture called RESET (rapamycin-enabled, switchable endogenous TCR) was developed to more closely mimic TCR activation, thus potentially improving T cell killing of low antigen expression tumor cells. RESET combines the antibody-based targeting of CARs, the drug-regulated activity of the DARIC (a rapamycin-regulated CAR) technology and the natural signaling proficiency and inherent sensitivity of TCRs. The RESET receptor comprises two functional units that are designed to enable toggling of RESET T cells between inert and activated states through rapamycin-induced dimerization: When challenged with low antigen density tumor cells in vitro, CD33-targeted RESET T cells (RESET33) were more potently reactive to CD33+ tumor cells after rapamycin dimerization, secreting approximately three times more cytokine than CD33-targeted regulated CAR T cells. This enhancement was also observed in preclinical NSG mouse models in vivo, where RESET33 T cells more deeply controlled systemic CD33+ AML tumor models, providing a significant survival benefit in comparison to DARIC33 T cells. A novel TGFβ switch receptor drove robust MAGE-A4 TCR anti-tumor activity with a favorable safety profile Solid tumors frequently secrete TGFβ, a pleiotropic cytokine that suppresses T cell responses. To counteract the immunosuppressive effects of TGFβ within engineered T cells, a synthetic receptor (CTBR12) was developed to leverage an immunosuppressive cytokine to convert TGFβ binding into pro-inflammatory signaling events that enhance anti-tumor function: T cells co-expressing a pairing enhanced MAGE-A4 TCR with the CTBR12 switch receptor demonstrated robust antigen-dependent responses that were significantly enhanced upon exposure to TGFβ, whereas MAGE-A4 TCR controls lacking CTBR12 were suppressed by this anti-inflammatory cytokine. CTBR12 co-expression did not alter the safety profile of the MAGE-A4 TCR. In two murine xenograft tumor models with abundant TGFβ, T cells co-expressing the MAGE-A4 TCR and CTBR12 both controlled tumors at T cell doses that elicited only minimal responses without CTBR12 co-expression and exhibited superior durability of response overall. About SC-DARIC33 SC-DARIC33 is an investigational CD33-specific cell therapy that utilizes 2seventy bio’s proprietary Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) T cell platform. SC-DARIC33 is designed as a regulatable, potentially first-in-class autologous T cell therapy and is now being studied at Seattle Children’s in a Phase 1 trial, PLAT-08 (NCT05105152), as a first-in-human investigation of the DARIC T cell platform in relapsed/refractory pediatric and young adult AML. DARIC separates the antigen binding and signaling functions of a CAR, with the intent that these two components are brought together by the small molecule rapamycin, resulting in a functional CAR construct. In preclinical studies, SC-DARIC33 has shown robust drug-dependent anti-tumor activity (similar to CD19 CAR T controls). Importantly, SC-DARIC33 has been shown to be activated by low non-immunosuppressive concentrations of rapamycin in the blood and, when rapamycin is removed, DARIC returns to an inactive state. SC-DARIC33 tests the hypothesis that a pharmacologically regulated CAR can enable potent AML targeting while limiting toxicities associated with normal myeloid and myeloid progenitor cell targeting. The investigation of SC-DARIC33 in the Phase 1 PLAT-08 study of pediatric and young adult AML patients and the scientific translation of these data are intended to establish the safety profile of SC-DARIC33 and evaluate feasibility of the reversable modulation (OFF-ON-OFF) of SC-DARIC33. SC-DARIC33 is not approved for any indication in any geography. About bbT369 bbT369 is an investigational dual-targeting CAR T cell therapy with a gene edit being evaluated for the treatment of patients with relapsed and/or refractory B-NHL currently being evaluated in a first-in-human Phase 1/2 trial (CRC-403 NCT05169489). bbT369 was purposely designed with three layers of innovation to address the potential mechanisms of anti-CD19 CAR T cell therapy failure, including dual targeting of CD79a/CD20, which is a novel combination of antigens highly expressed in B cell lymphomas, a split co-stimulation signaling technology intended to drive more robust T cell activation, and a gene edit to remove the function of CBLB, a known negative regulator of T cells. In the 3L+ relapsed and/or refractory B-NHL setting, 60-70% of patients treated with commercially available CAR T cell therapies do not achieve a long-term remission, highlighting a significant unmet clinical need. In December 2021, the FDA cleared the Investigational New Drug (IND) application for bbT369. The clinical development program for bbT369 includes the Phase 1/2 CRC-403 study (NCT05169489). Safety and potential efficacy of bbT369 in patients with specific subtypes of relapsed and/or refractory B-NHL will be assessed, including patients who relapsed after CD19 CAR T cell therapy as well as patients who are CAR-naïve. bbT369 is not approved for any indication in any geography. About the MAGE-A4 Program MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. The program employs a highly potent TCR discovered in our MediGene collaboration that recognizes HLA-presented MAGE-A4 peptides and further enhances the potency of these re-directed T cells using our CTBR12 TGFβ “flip” receptor technology -- which converts the immunosuppressive effects of TGFβ into an activation signal for the T cells. Regeneron and 2seventy bio are co-developing the program under their collaboration entered into in 2018. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day. For more information, visit www.2seventybio.com. Follow 2seventy bio on social media: Twitter and LinkedIn. 2seventy bio is a trademark of 2seventy bio, Inc. Cautionary Note Regarding Forward-Looking Statements of 2seventy bio This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the research, development, manufacture or sale of our product candidates, including the results of ongoing and planned pre-clinical studies and clinical trials; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; and statements about our ability to execute our strategic priorities. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the pre-clinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect 2seventy bio’s business, particularly those identified in the risk factors discussion in 2seventy bio’s Annual Report on Form 10-K, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, 2seventy bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.